The synergistic effect of depression and moderate chronic kidney disease on the all-cause and cardiovascular disease mortality among adults: a retrospective cohort study

Fanchao Meng, Yanjie Qi, Xu Chen, Xiuping Yan, Huanhuan Huang and Fan He*

Abstract

Background: The relationship between the coexistence of depression and moderate chronic kidney disease (CKD) and mortality is unclear. We aimed to investigate whether there is a synergistic effect of depression and moderate CKD on the all-cause and cardiovascular disease (CVD) mortality among adults.

Methods: We studied 24,412 participants from the National Health and Nutrition Examination Survey 2005–2014 with a mortality follow-up assessment in 2015. Four groups were created based on depression and CKD status: Group 1, no depression and no CKD; Group 2, depression present and no CKD; Group 3: no depression and CKD present; Group 4: depression present and CKD present. Moderate CKD was defined as an estimated glomerular filtration rate of 15–59 mL/min/1.73 m² (Stage 3–4) or one-time urine albumin-to-creatinine ratio $\geq 30$ mg/g. Depression was defined as the 9-item Patient Health Questionnaire score of 10 or more. Cox proportional hazards regression models were used to calculate the multivariate-adjusted hazard ratios (HRs) of death for Group 4 with other groups.

Results: Over a mean follow-up of 5.8 years, 1783 deaths were documented, including 338 deaths from CVD. The HR for all-cause mortality in Group 4 was 3.62 (95% CI: 2.69–4.87), 2.99 (1.92–4.66), and 1.75 (1.29–2.37) when compared with Group 1, 2, and 3, respectively. The HR for CVD mortality in Group 4 was 3.89 (1.68–9.00), 1.90 (0.86–4.21), and 1.97 (1.17–3.32) when compared with Group 1, 2, and 3, respectively.

Conclusions: There might be a synergistic effect of depression and moderate CKD on all-cause mortality. Moreover, depression might increase the risk of CVD mortality in individuals with moderate CKD.

Keywords: Chronic kidney disease, Depression, Mortality, Cardiovascular disease

Introduction

Depression is a mood disorder that limits psychosocial functioning and diminishes the quality of life. The lifetime risk of depression is 15–18%, meaning that it is common among the population [1]. There is fairly consistent evidence that depression is associated with increased mortality [2, 3] and poor cardiovascular outcomes [4, 5].
Chronic kidney disease (CKD) is also highly prevalent both in the US and China [6, 7], and multiple studies have documented an increased prevalence of depression in the population with CKD [8]. Previous studies have identified depression as an independent risk factor for death in CKD patients receiving maintenance dialysis [9, 10]. In addition, a meta-analysis, which included 22 studies and 83,381 participants, found that depression consistently increased the risk of all-cause mortality [Risk ratio (RR), 1.59; 95% confidence interval (CI): 1.35–1.87] among adults with CKD [11]. However, the data for individuals with moderate CKD (Stage 3–4) were limited in this study and antidepressant medication use was not adjusted. Moreover, this study did not prove a certain effect of depression on cardiovascular disease (CVD) mortality (RR, 1.88; 95% CI: 0.84–4.19).

Therefore, the relationship between the coexistence of depression and moderate CKD and mortality is worth further exploring. In particular, there is no adequate evidence that proves the effect of depression on the risk of death in people with and without moderate CKD. In this study, we aimed to investigate whether there is a synergistic effect of depression and moderate CKD on the all-cause and CVD mortality among adults.

Methods

Data source

We examined the mortality in a nationally representative cohort from the National Health and Nutrition Examination Surveys (NHANES). The NHANES is a series of independent health surveys of the US civilian, noninstitutionalized population conducted by the National Center for Health Statistics (NCHS). Since 1999, NHANES collected data continuously and released datasets in 2-year cycles. In each survey, participants are selected with the use of a complex, stratified, multistage probability-cluster sampling design for in-home interviews and visits to a mobile examination center [12]. We included data from NHANES 2005–2014 as the NHANES used a different rating scale for depression before 2005. The data from NHANES is openly available at https://www.cdc.gov/nchs/nhanes/index.htm. The NCHS approved the study protocols and written informed consent was obtained from each participant [13]. This study followed the STROBE checklist for observational studies.

Definition of covariates

During the in-home interview, demographic and health-related information was collected by standardized questionnaires [12]. Current smoking was self-reported based on questions about whether participants were currently smoking or not. Current excessive alcohol use was defined as drinking, on average, ≥ 5 drinks/day in the 12 months preceding the survey interview. For the antidepressant medication, participants were asked if they had taken any prescription drug in the past 30 days and antidepressant medication was determined using the second level of drug ingredient categorical codes. A combination of bupropion and naltrexone, which is primarily used for obesity, overweight, and weight-related medical problems, was excluded [14]. History of CVD and cancer was ascertained by self-report and CVD included stroke, congestive heart failure, angina, and myocardial infarction.

Weight and height were measured during the examination and the body mass index (BMI) was defined as weight in kilograms divided by height in meters squared. Blood pressure (BP) was measured and mean BP was calculated as the mean of three readings according to the standardized protocol. Blood samples were collected at the mobile examination center, stored at −20 °C, and sent to the central laboratories for the measurement of hemoglobin A1c, total cholesterol, and serum creatinine. Urine albumin and creatinine were measured in the same laboratory during the surveys.

Obesity was defined as BMI of 30 or higher; hypertension as systolic BP of 130 mmHg or higher, diastolic BP of 80 mmHg or higher, or the use of antihypertensive medications; diabetes as hemoglobin A1c of 6.5% or higher, or the use of antidiabetic medications; dyslipidemia as total cholesterol of 240 mg/dL or higher, or the use of lipid-lowering medications.

We calculated the estimated glomerular filtration rate (eGFR) based on serum creatinine by using the Chronic Kidney Disease Epidemiology Collaboration equation [15]. Calibrations for the measurements of serum creatinine in different surveys were conducted according to the recommendation of NHANES. Moderate CKD (stage 3–4) was defined as an eGFR of 15–59 ml/min/1.73 m² or a one-time urine albumin-to-creatinine ratio ≥ 30 mg/g. Patients with an eGFR < 15 ml/min/1.73 m², corresponding to CKD stage 5 (end-stage CKD), were excluded.

Depression was assessed using the 9-item Patient Health Questionnaire (PHQ-9) according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV). The PHQ-9 is a screening instrument that asks about the frequency of symptoms of depression over the past 2 weeks. We defined major depression as the summed score on the PHQ-9 of 10 points or greater. The use of a PHQ-9 score of 10 points has been proven to provide a favorable balance between sensitivity and specificity [16].

Ascertainment of mortality

Mortality data were retrospectively ascertained by linkage to the National Death Index through December 31,
2015. The International Classification of Diseases-10 was used to determine disease-specific mortality. According to the Codebook for the 2015 Public-Use Linked Mortality File, CVD mortality included heart disease mortality and stroke mortality [17].

Statistical analysis
To account for oversampled population, appropriate 10-year sampling weights were constructed according to the NHANES recommendation. All statistical analysis was conducted in R version 4.1.0 with the “Survey” package after accounting for the complex sampling design. All statistical tests were 2-sided, and \( P<0.05 \) was considered statistically significant. We restricted our participants to non-pregnant adults aged 18 years or older. Continuous variables were expressed as means (standard error) and categorical variables as percentages (standard error) in the four different groups. Group 1 was defined as participants without depression and without moderate CKD, Group 2 as participants with depression and without moderate CKD, Group 3 as participants without depression and with moderate CKD, and Group 4 as participants with both depression and moderate CKD. Mortality was expressed as events per 1000 person-years of follow-up. The number of person-years of follow-up time was calculated from the time of entry into the study until the date of death or the termination day of follow-up. Life expectancy and survival times for four groups were estimated by the Kaplan-Meier product-limit method.

Cox proportional hazards regression models were used to calculate multivariate-adjusted hazard ratios (HRs) of death across different groups. We calculated native HR in model 0 without adjusting for any confounders. We also calculated adjusted HRs in three different models. Model 1 was adjusted for age, gender, race, and education. Model 2 was further adjusted for obesity, diabetes, hypertension, dyslipidemia, history of cardiovascular disease, and history of cancers based on Model 1. Model 3 was further adjusted for current smoke, current excessive alcohol use, antidepressant medication, eGFR, and albumin-to-creatinine ratio based on model 2. Three pairs of post hoc comparisons with Bonferroni correction were conducted after the main analysis to test the difference of death in Group 4 with death in the other three groups [18]. A \( P \)-value less than 0.017 was considered statistically significant in the post hoc analysis.

We conducted several sensitivity analyses to test the robustness of the results. First, to account for the difference in the definition of CKD, we redefined CKD as an eGFR of 15 to 59 mL/min/1.73 m\(^{2}\) alone without considering the urine albumin-to-creatinine ratio. Second, to account for the potential effects of age on the outcomes, we excluded young adults in the analysis and restricted our participants to those aged 45 years or older. Third, to account for the interaction between depressive symptoms and functional impairment, we compared mortality rates among four groups of participants based on the presence or absence of functional impairment and moderate CKD. In these sensitivity analyses, we only compared the all-cause mortality in different groups owing to the small number of CVD death events.

Results
The baseline characteristics of participants are presented in Table 1. Our final data set comprised 24,412 participants. In general, compared to those without depression, depressed participants with or without CKD were younger, less likely to be male and non-Hispanic white, received less education, more likely to be current smokers and current excessive alcohol and antidepressant users, more likely to be obese, and more likely to have a history of hypertension, diabetes, dyslipidemia, CVD, and cancer.

All-cause mortality
Table 2 presents all-cause and CVD mortality rates and adjusted HRs of death. The mean follow-up period was 5.8 years and a total of 1783 deaths from all-cause were recorded. The all-cause mortality rate was 5.2, 6.9, 32.8, and 46.6 per 1000 person-years in Group 1, Group 2, Group 3, and Group 4, respectively. Figure 1 shows the Kaplan-Meier survival curves of unadjusted all-cause mortality for four different groups. In model 1, model 2, and model 3, when compared with Group 1, adjusted HRs for deaths from all-cause were significantly higher in Group 2 and Group 3 but were highest in Group 4. In the post hoc comparison, adjusted HRs for deaths from all-cause were significantly higher in Group 4 when compared with Group 1 in model 1 (HR, 4.18; 95% CI, 3.26–5.35; \( P<0.001 \)), model 2 (HR, 3.44; 95% CI, 2.61–4.53; \( P<0.001 \)) and model 3 (HR, 3.62; 95% CI: 2.69–4.87; \( P<0.001 \)). The adjusted HRs for deaths from all-cause in Group 4 were all significantly higher when compared with Group 2 and Group 3 in model 1, model 2, and model 3.

In the sensitivity analysis with the definition of CKD as an eGFR of 15 to 59 mL/min/1.73 m\(^{2}\) alone, Group 4 had significantly higher adjusted HRs for all-cause mortality rate when compared with Group 1, Group 2, and Group 3 in model 1 and model 2 (Supplemental Table 1). In model 3, Group 4 had a higher adjusted HR (1.61; 95% CI: 1.02–2.56) when compared with Group 3. However, the \( P \)-value (0.042) was larger than 0.017 and should not be considered statistically significant in the post hoc analysis. In another two sensitivity analyses, Group 4 had significantly higher adjusted HRs for all-cause mortality
rate when compared with Group 1, Group 2, and Group 3 in model 1, model 2, and model 3 (Supplemental Table 1). The Kaplan-Meier survival curves of unadjusted all-cause mortality for four different groups in the sensitivity analyses were presented in Supplemental Fig. 1, 2, and 3.

CVD mortality
A total of 338 individuals died from CVD. The CVD mortality rate was 0.8, 1.5, 6.6, and 10.3 per 1000 person-years in Group 1, Group 2, Group 3, and Group 4, respectively. Figure 2 shows the Kaplan-Meier survival curves of unadjusted CVD mortality for four different groups. In model 1, model 2, and model 3, adjusted HRs for deaths from CVD were significantly higher in Group 2 and Group 3 but were highest in Group 4. In model 1, model 2, and model 3, when compared with Group 1, adjusted HRs for deaths from CVD were significantly higher in Group 2 and Group 3 but were highest in Group 4.

In the post hoc comparison, adjusted HRs for deaths from CVD were significantly higher in Group 4 when compared with Group 1 in model 1 (HR, 5.64; 95% CI, 3.43–9.25; P < 0.001), model 2 (HR, 3.92; 95% CI, 2.21–6.94; P < 0.001) and model 3 (HR, 3.89; 95% CI: 1.68–9.00; P = 0.002). The adjusted HRs for deaths from CVD in Group 4 were also significantly higher when compared with Group 3 in model 1 (HR, 2.25; 95% CI, 1.44–3.50; P < 0.001), model 2 (HR, 2.00; 95% CI, 1.19–3.35; P = 0.009), and model 3 (HR, 1.97; 95% CI, 1.17–3.32; P = 0.011). However, the adjusted HRs for deaths from CVD in Group 4 were not statistically significant higher when compared with Group 2 in model 1 (HR, 2.64; 95% CI: 1.19–5.85; P = 0.0173), model 2 (HR, 2.01; 95% CI: 0.93–4.34; P = 0.074), and model 3 (HR, 1.90; 95% CI: 0.86–4.21; P = 0.112).

Discussion
In this study, we demonstrated that there might be a synergistic effect of depression and moderate CKD on all-cause mortality. After adjusting for clinically potential confounders, people with both depression and moderate CKD are 1.75 times as likely to die from all-cause mortality when compared with those with moderate CKD alone,

### Table 1 Baseline characteristics of participants by presence or absence of CKD and depression, NHANES 2005–2014

|                        | Group 1 Without CKD and without depression | Group 2 Without CKD and with depression | Group 3 With CKD and without depression | Group 4 With CKD and with depression |
|------------------------|--------------------------------------------|----------------------------------------|----------------------------------------|-------------------------------------|
| Number of Participants | 18,334                                     | 1695                                   | 3928                                   | 455                                 |
| Age, year              | 44.3 (0.3)                                 | 44.1 (0.5)                             | 60.2 (0.5)                             | 56.2 (0.9)                          |
| Male, %                | 52.0 (0.4)                                 | 36.4 (1.6)                             | 43.7 (1.1)                             | 32.1 (2.6)                          |
| Race/ethnicity, %      |                                            |                                        |                                        |                                     |
| Mexican American       | 13.5 (1.0)                                 | 16.1 (1.6)                             | 11.2 (1.0)                             | 16.0 (2.1)                          |
| Non-Hispanic white     | 70.0 (1.5)                                 | 64.8 (2.2)                             | 72.2 (1.5)                             | 61.5 (3.0)                          |
| Non-Hispanic black     | 10.1 (0.8)                                 | 13.2 (1.2)                             | 11.6 (0.9)                             | 18.2 (2.1)                          |
| Other                  | 6.5 (0.4)                                  | 5.9 (0.7)                              | 5.0 (0.5)                              | 4.3 (1.1)                           |
| Education, %           |                                            |                                        |                                        |                                     |
| Less than high school  | 15.7 (0.7)                                 | 272.1 (1.6)                            | 23.1 (0.9)                             | 35.5 (3.1)                          |
| High school graduate   | 22.6 (0.6)                                 | 27.2 (1.5)                             | 25.6 (1.2)                             | 25.9 (2.9)                          |
| Some college           | 31.6 (0.6)                                 | 33.1 (1.5)                             | 29.4 (1.0)                             | 32.0 (3.0)                          |
| College graduate or higher | 30.1 (1.0)    | 12.5 (1.4)                             | 22.0 (1.2)                             | 6.6 (1.8)                           |
| Current smoke, %       | 20.4 (0.6)                                 | 40.7 (1.8)                             | 15.8 (0.7)                             | 33.9 (3.2)                          |
| Current excessive alcohol use, % | 11.8 (0.4) | 15.2 (1.0)                             | 6.2 (0.6)                              | 9.0 (1.5)                           |
| Antidepressant medication, % | 19.7 (0.6) | 48.6 (2.1)                             | 18.2 (0.9)                             | 45.0 (3.1)                          |
| Obesity, %             | 33.1 (0.6)                                 | 44.3 (1.7)                             | 41.7 (1.1)                             | 55.6 (3.2)                          |
| Hypertension, %        | 40.1 (0.6)                                 | 44.8 (1.5)                             | 72.5 (1.0)                             | 74.9 (2.8)                          |
| Diabetes, %            | 6.8 (0.2)                                  | 11.7 (1.2)                             | 26.8 (1.0)                             | 398 (2.5)                           |
| Dyslipidemia, %        | 248 (0.5)                                  | 290 (1.6)                              | 45.8 (1.2)                             | 482 (3.2)                           |
| History of CVD, %      | 5.4 (0.2)                                  | 12.6 (1.0)                             | 23.2 (1.0)                             | 364 (3.1)                           |
| History of Cancer, %   | 8.3 (0.3)                                  | 11.7 (1.1)                             | 17.1 (0.7)                             | 144 (2.2)                           |
| eGFR, mL/min/1.73 m²   | 98.1 (0.3)                                 | 99.3 (0.6)                             | 72.8 (0.7)                             | 760 (1.8)                           |
| Albumin-to-creatinine ratio, mg/g | 7.6 (0.1) | 8.3 (0.2)                             | 150.0 (10.1)                          | 2699 (35.4)                         |

CKD chronic kidney disease, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, NHANES National Health and Nutrition Examination Surveys
2.99 times as likely to die from all-cause compared with those with depression alone, and 3.62 times as likely to die from all-cause compared with those without either depression and moderate CKD. In addition, depression might increase the risk of CVD mortality in individuals with moderate CKD as those with both depression and moderate CKD are 1.97 times as likely to die from CVD mortality compared to those with moderate CKD alone.

Numerous studies of end-stage renal disease patients receiving maintenance dialysis reported an association between depression and increased risk of poor outcomes, including death [9, 10, 19–21]. However, the number of studies evaluating the relationship between depression in people with moderate CKD and mortality is limited. Hedayati et al. explored the association between major depressive episodes in 267 participants with CKD (stage 2–5 and who were not receiving dialysis) and a composite of death, dialysis initiation, or hospitalization in a prospective cohort study with one-year follow-up [22]. They found that the presence of depression was associated with an increased risk of a composite of events in CKD patients. However, in this study, the relationship between depression and death was not significant, which might be due to the small number of participants. Even though depression in moderate CKD was proved to be an independent predictor of adverse clinical outcomes in these studies, its relationship with mortality was not clearly defined. To our knowledge, the current study was the first that reports a significant synergistic effect of depression and moderate CKD on mortality among adults. This effect was robust and independent of demographic factors, medical comorbidities, and especially the antidepressant medication.

There is accumulating evidence that patients with CKD exhibit a pronounced risk for CVD and that it is associated with increased CVD mortality [23, 24]. Similarly, considerable evidence proves that depression is associated with a significantly increased risk of CVD mortality [4, 25–27]. The results of our study were consistent with previous findings. Compared with people without depression.
Fig. 1 Estimated probability of survival (all-cause mortality) according to depression and moderate CKD status. CKD: chronic kidney disease.

Fig. 2 Estimated probability of survival (cardiovascular disease mortality) according to depression and moderate CKD status. CKD: chronic kidney disease.
moderate CKD and without depression, those with moderate CKD alone had 1.89-fold increased CVD mortality and those with depression alone had 2.33-fold increased CVD mortality. Moreover, even though individuals with both depression and moderate CKD did not have a significantly higher risk of CVD mortality compared with those with depression alone after adjusting for all the potential confounders, they had a 1.97-fold increased CVD mortality when compared with those with moderate CKD alone. These findings suggested that depression might be a stronger predictor of CVD mortality than moderate CKD in this cohort and depression accounts for most of the increased risk of CVD mortality in individuals with both depression and moderate CKD.

The underlying mechanisms that depression increases mortality are unclear. Suicide is a clear mechanism through which depression increases mortality. Another plausible mechanism is nonadherence to medical advice, which is consequently associated with decreased survival [28]. Furthermore, persistent depression would worsen physical health over time and psychological distress with subsequent neurohormonal changes is thought to increase susceptibility to disease [29]. However, it remains unclear whether depression itself has a direct impact on the development of mortality in CKD or whether depression is just a surrogate marker for comorbidity and CVD severity [9]. Our study found that after adjusting for comorbidity and other risk factors, the association between depression and mortality remains significant even though the HR decreased, indicating that depression might have both direct and indirect effects on mortality in patients with CKD.

The limitations of this study should be noted. First and most important, the measurement of serum creatinine and urine albuminuria was only available at a single point in time in NHANES and it might lead to the misclassification of CKD status. However, the misclassification should be non-differential across survey years and it is not likely to bias our analysis. Second, we did not include some other factors such as inflammation, morbidity, or mineral bone disease as confounders since they were not complete or available in the NHANES. Notwithstanding, this is not unprecedented and previous similar studies also did not include them as confounders [22, 30, 31]. Third, we used self-reported questionnaires, making data susceptible to recall and information biases. However, self-reported information on depression and CVD risk factors has been widely used in epidemiological studies and the results are reliable. Fourth, the current study was observational and it is unlikely to determine whether depression is causally related to excessive mortality risk in individuals with moderate CKD. Last, the number of CVD events in the follow-up was relatively small and we are not able to evaluate the impact of depression on CVD mortality in the sensitivity analyses. Thus, the interpretation of the significant association between depression and CVD mortality in individuals with moderate CKD should be with caution.

Despite these potential limitations, the results of this study remain meaningful. There might be a synergistic effect of depression and moderate CKD on all-cause mortality. Moreover, depression might increase the risk of CVD mortality in individuals with moderate CKD.

**Abbreviations**

BP: Blood pressure; BMI: Body mass index; CI: Confidence interval; CKD: Chronic kidney disease; CVD: Cerebrovascular disease; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; eGFR: Estimated glomerular filtration rate; HR: Hazard ratio; RR: Risk ratio; NCHS: National Center for Health Statistics; NHANES: National Health and Nutrition Examination Surveys; PHQ-9: 9-item Patient Health Questionnaire.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12882-022-02957-7.

**Additional file 1: Supplemental Table 1.** Hazard ratio of all-cause mortality in the sensitivity analysis. Supplemental Fig. 1. Estimated probability of survival (all-cause mortality) according to depression and earlier-stage CKD status in sensitivity analysis with the definition of CKD as eGFR of 15–59 mL/min/1.73m² alone. CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate. Supplemental Fig. 2. Estimated probability of survival (all-cause mortality) according to depression and earlier-stage CKD status in sensitivity analysis with participants aged 45 years or older. CKD: chronic kidney disease. Supplemental Fig. 3. Estimated probability of survival (all-cause mortality) according to functional impairment and earlier-stage CKD status. CKD: chronic kidney disease.

**Acknowledgments**

We’d like to thank the staff of the National Center for Health Statistics for conducting the surveys and providing the data.

**Authors’ contributions**

Fanchao Meng designed the study and conducted the statistical analysis. Yanjie Qi, Xu Chen, Xiuping Yan, and Huanhuan Huang prepared the data and manuscript. He Fan reviewed the results and revised the manuscript. The author(s) read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

The data is from the National Health and Nutrition Examination Survey and is openly available at https://www.cdc.gov/nchs/nhanes/index.htm.

**Declarations**

**Ethics approval and consent to participate**

The National Center for Health Statistics institutional review board approved the study protocols. Written informed consent was obtained from each participant and from the legal representative of the dead participants. All methods were carried out in accordance with relevant guidelines and regulations.
The authors have no conflicts of interest to declare.

Consent for publication
Not applicable.

Competing interests
Not applicable.

References
1. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, De Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):1–16.
2. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med. 1999;61(1):6–17.
3. Gilman SE, Sucha E, Kingsbury M, Horton NJ, Murphy JM, Colman I. Depression and mortality in a longitudinal study. 1952–2011. Cmaj. 2017;189(42):E1304–E10.
4. Meng R, Yu C, Liu N, He M, Lv J, Guo Y, et al. Association of depression with all-cause and cardiovascular disease mortality among adults in China. JAMA Netw Open. 2020;3(2):e1921043-e.
5. Wei J, Lu Y, Li K, Goodman M, Xu H. The associations of late-life depression with all-cause and cardiovascular mortality: the NHANES 2005–2014. J Affect Disord. 2020;330:189–94.
6. Coresh J, Selvin E, Stevens LA, Manji Z, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007;298(17):2038–47.
7. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.
8. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–91.
9. Hedayati SS, Bosworth HB, Horley LP, Sloan RJ, Pieper CF, Kimmel PL, et al. Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int. 2008;74(7):930–6.
10. Hedayati SS, Grambow SC, Szczezak LA, Stechuchak KM, Allen AS, Bosworth HB. Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. Am J Kidney Dis. 2005;46(4):642–9.
11. Palmer SC, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Association between depression and death in people with CKD: a meta-analysis of cohort studies. Am J Kidney Dis. 2013;62(3):493–505.
12. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey [Available from: https://www.cdc.gov/nchs/nhanes/index.htm]. Accessed 15 Mar 2022.
13. Centers for Disease Control and Prevention. NCHS Research Ethics Review Board (ERB) Approval [Available from: https://www.cdc.gov/nchs/nhanes/irba98.htm]. Accessed 22 Aug 2022.
14. Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015–2018[M]. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2020.
15. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HJ, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
16. Koenig K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
17. Centers for Disease Control and Prevention. Codebook for the 2015 Public Use Linked Mortality File (LMF). [Available from: https://www.cdc.gov/nchs/data/datalinkage/public-use-2015-linked-mortality-files-data-dictionary.pdf]. Accessed 23 Feb 2022.
18. Tripathi A, Pandey A. Post-hoc comparison in survival analysis: an easy approach. J Biosci Med. 2017;5(3):112.
19. Farrokh F, Abedi N, Beyene J, Kundra J, Jassal SV. Association between depression and mortality in patients receiving long-term dialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63(4):623–35.
20. Wai L, Burton H, Richmond J, Lindsay R. Influence of psychosocial factors on survival of home-dialysis patients. Lancet. 1981;318(8256):1155–6.
21. Source JM, McClellan WM. Early death in dialysis patients: risk factors and impact on incidence and mortality rates. J Am Soc Nephrol. 1996;7(10):2169–75.
22. Hedayati SS, Minahuddin AT, Afshar M, Toto RD, Trivedi MH, Rush AJ. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. Jama. 2010;303(19):1946–53.
23. Ganssvoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9908):339–52.
24. Sarnak MJ, Levey AS, Schoolwerth AC, Coris J, Cukelton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108(17):2154–69.
25. Pan A, Sun Q, Okereme Ol, Rezvode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. Jama. 2011;306(11):1241–9.
26. Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R, et al. Association of symptoms of depression with cardiovascular disease and mortality in low-, middle-, and high-income countries. JAMA Psychiat. 2020;77(10):1052–63.
27. Machado MO, Veronese N, Sanches M, Stubbs B, Koyanagi A, Thompson T, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 2018;16(1):1–13.
28. Kimmel PL, Peterson RA, Wehs KL, Simmons SJ, Alleyne S, Cruz I, et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int. 1998;54(1):245–54.
29. Carney RM, Freedland KE, Miller GE, Jaffe AS. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res. 2002;53(4):897–902.
30. Tsai Y-C, Chiu Y-W, Hung C-C, Hwang S-J, Tsai J-C, Wang S-L, et al. Association of symptoms of depression with cardiovascular disease mortality among adults in Taiwan. J Am Heart Assoc. 2012;60(1):54–61.
31. Feng L, Yap KB, Ng TP. Depressive symptoms in older adults with chronic kidney disease: mortality, quality of life outcomes, and correlates. Am J Geriatr Psychiatry. 2013;21(6):570–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.